文献速递肝病消化道肿瘤与早癌

定制纳米氧化铈:实验性肝细胞癌的有效治疗

Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2020-01-01

该研究在二乙基亚硝胺诱导的110只Wistar大鼠肝细胞癌模型中,于第16和17周给予纳米氧化铈(CeO2 NPs)治疗。结果显示纳米氧化铈主要蓄积于肝脏,减少巨噬细胞浸润和炎症基因表达,增加凋亡、抑制增殖,降低血清甲胎蛋白水平并改善生存,且人离体灌注肝脏和体外原代人肝细胞可摄取纳米氧化铈。

要点

  • 纳米氧化铈在HCC大鼠中主要蓄积于肝脏并减少巨噬细胞浸润。
  • 纳米氧化铈增加肝脏凋亡活性并抑制增殖。
  • 纳米氧化铈降低血清甲胎蛋白水平并改善HCC大鼠生存。

核心结论

  • 纳米氧化铈可部分逆转HCC肿瘤进展相关细胞机制并显著提高HCC大鼠生存率,提示可能对HCC患者有效。

研究设计与样本

  • 在110只Wistar大鼠中通过腹腔注射二乙基亚硝胺16周诱导HCC,于第16和17周给予溶媒或纳米氧化铈治疗。

主要发现

  • 纳米氧化铈主要蓄积于肝脏,减少巨噬细胞浸润和炎症基因表达。
  • 纳米氧化铈治疗增加肝脏凋亡活性,同时增殖受到抑制。
  • 磷酸化蛋白质组学显示纳米氧化铈主要影响细胞黏附和RNA剪接相关蛋白的磷酸化。
  • 纳米氧化铈降低磷脂酰胆碱来源的花生四烯酸并逆转HCC诱导的多种脂质组分中亚油酸升高。
  • 纳米氧化铈降低血清甲胎蛋白水平并改善HCC大鼠生存。

临床怎么用

  • 纳米氧化铈在HCC大鼠中显示抗肿瘤和改善生存的作用,支持进一步开展临床转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Despite the availability of new-generation drugs, hepatocellular carcinoma (HCC) is still the third most frequent cause of cancer-related deaths worldwide. Cerium oxide nanoparticles (CeO2 NPs) have emerged as an antioxidant agent in experimental liver disease because of their antioxidant, anti-inflammatory, and antisteatotic properties. In the present study, we aimed to elucidate the potential of CeO2 NPs as therapeutic agents in HCC. APPROACH AND RESULTS: HCC was induced in 110 Wistar rats by intraperitoneal administration of diethylnitrosamine for 16 weeks. Animals were treated with vehicle or CeO2 NPs at weeks 16 and 17. At the eighteenth week, nanoceria biodistribution was assessed by mass spectrometry (MS). The effect of CeO2 NPs on tumor progression and animal survival was investigated. Hepatic tissue MS-based phosphoproteomics as well as analysis of principal lipid components were performed. The intracellular uptake of CeO2 NPs by human ex vivo perfused livers and human hepatocytes was analyzed. Nanoceria was mainly accumulated in the liver, where it reduced macrophage infiltration and inflammatory gene expression. Nanoceria treatment increased liver apoptotic activity, while proliferation was attenuated. Phosphoproteomic analysis revealed that CeO2 NPs affected the phosphorylation of proteins mainly related to cell adhesion and RNA splicing. CeO2 NPs decreased phosphatidylcholine-derived arachidonic acid and reverted the HCC-induced increase of linoleic acid in several lipid components. Furthermore, CeO2 NPs reduced serum alpha-protein levels and improved the survival of HCC rats. Nanoceria uptake by ex vivo perfused human livers and in vitro human hepatocytes was also demonstrated. CONCLUSIONS: These data indicate that CeO2 NPs partially revert the cellular mechanisms involved in tumor progression and significantly increase survival in HCC rats, suggesting that they could be effective in patients with HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Fernández-Varo G, Perramón M, Carvajal S, et al. Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma. Hepatology. 2020. PMID: 31961955. doi:10.1002/hep.31139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。